CMS Guidance On Desired Data Might Meet The Goals Of Parallel Review More Reasonably, Former Official Gottlieb Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
AEI's Scott Gottlieb, a former official at FDA and CMS, offers his insights into the proposed parallel review program during Avalere conference.
You may also be interested in...
IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
BALTIMORE – Decisions by the soon-to-be-created Independent Payment Advisory Board could make CMS participation in parallel review of drugs with FDA much more meaningful than it would otherwise be, assuming the health care reform law remains intact, former CMS and FDA official Scott Gottlieb said.
IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
BALTIMORE – Decisions by the soon-to-be-created Independent Payment Advisory Board could make CMS participation in parallel review of drugs with FDA much more meaningful than it would otherwise be, assuming the health care reform law remains intact, former CMS and FDA official Scott Gottlieb said.
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
The two major trade associations representing drug and biological manufacturers are telling FDA and CMS that their proposed parallel review process is neither appropriate nor necessary for biopharma products.